#USA #FrontlineODP #Beverly #Velico Medical #Spray Dried Plasma

Velico Announces Major Manufacturing and Supply Chain Expansion

In response to increasing demands for its innovative FrontlineODP™ Spray Dried Plasma Manufacturing System, Velico Medical, Inc. has revealed plans for a substantial expansion in its manufacturing and supply chain operations. This move is part of their broader strategy to enhance the availability of life-saving dried plasma, a critical resource in emergency and battlefield medical situations.

The FrontlineODP™ System

The FrontlineODP™ system is at the forefront of this development. It enables both military and civilian blood centers to take liquid donor plasma and produce dried plasma in just 30 minutes. The dried plasma is contained in an ultra-lightweight plastic bag that boasts a shelf life of up to two years. This duration ensures both stability and ease of deployment in emergency settings. One remarkable feature of this product is its quick rehydration capability, allowing it to be ready for use in under three minutes — a crucial factor in delivering immediate care to patients suffering from severe bleeding.

Decentralized Manufacturing Approach

Velico's vision does not end with manufacturing enhancement; it encompasses the establishment of a decentralized manufacturing model. This approach aims to create a vast network of blood centers worldwide, each capable of producing tens of thousands of plasma units annually. With expansion plans that include key markets in North America, Europe, and the Indo-Pacific region, Velico anticipates that the combined production of compact and already contracted FrontlineODP™ systems will surpass 100,000 units per year.

Investing in Infrastructure

To align with this growing demand, Velico is in the final stages of planning new facilities in Europe and the Indo-Pacific to manufacture FrontlineODP™ consumables. Each of these new, fully automated production facilities is designed to produce up to 250,000 units annually. When combined with their two existing manufacturing sites in the U.S., Velico's total output could approach one million units of spray-dried plasma each year. Such capacity will significantly streamline emergency medical services, especially during critical situations, ensuring that vital resources are available and ready for immediate use.

Leadership Insights

Richard Meehan, President and CEO of Velico, emphasized the significance of this expansion: "For years, Velico has invested heavily in research and development to provide mass availability of life-saving dried plasma. As global adoption accelerates, we are scaling our manufacturing capabilities to meet unprecedented demand and ultimately reduce deaths from hemorrhage worldwide."
Adding to this, Andrew Racicot, the newly appointed Vice President of Manufacturing, stated, "Expanding our global manufacturing footprint strengthens Velico's ability to deliver efficiency, consistency, and quality. Our goal is to ensure that life-saving plasma is available precisely when and where it's needed the most."

Final Note

It is important to note that the FrontlineODP™ Spray Dried Plasma System is still under investigational status and is limited by U.S law to investigational use. The regulatory pathways for approval will vary across different countries and regions, contingent on specific local regulations. Velico's development program has received partial funding from the U.S. Department of Health and Human Services, reflecting government support for innovations aimed at improving emergency medical outcomes.

In conclusion, Velico's ambitious expansion highlights a pivotal moment in the integration of medical technology, emergency care, and trauma management, supporting a mission dedicated to saving lives worldwide. For more information about their initiatives, please visit their official website at www.veli.co.